Oncologist. 2026 Nov 13:oyag437. doi: 10.1093/oncolo/oyag437. Online ahead of print.
ABSTRACT
OBJECTIVE: To evaluate sex differences in liver metastases at diagnosis across major gastrointestinal adenocarcinomas and assess variation by primary site and age.
DESIGN, SETTING, AND PARTICIPANTS: Population-based cross-sectional study using Surveillance, Epidemiology, and End Results data (2012-2022). Patients aged 15 years or older with colorectal, esophagogastric, pancreatic, or biliary adenocarcinoma and known status of liver metastasis at diagnosis were selected. Patients with concurrent extrahepatic metastases were included.
EXPOSURE: Sex and age.
MAIN OUTCOMES AND MEASURES: Prevalence of synchronous liver metastases documented at diagnosis. Prevalence ratios (PRs) were estimated using modified Poisson regression with robust variance, adjusting for age, primary site, and year of diagnosis. Effect modification by primary site and age was assessed.
RESULTS: Among 410,439 patients, the overall prevalence of liver metastases was 22.2% and higher in males than females (23.5% vs 20.6%). Female sex was associated with a lower prevalence of liver metastases (adjusted PR 0.86; 95% CI, 0.85-0.87; P < 0.001). Effect modification by primary site was observed (P for interaction < 0.001): females had lower prevalence in colorectal (PR 0.84), esophagogastric (PR 0.69), and pancreatic (PR 0.89), higher prevalence in extrahepatic biliary (PR 1.14), and no significant difference in intrahepatic biliary cancers (PR 1.04). There was also evidence of effect modification by age (P for interaction < .001), with sex differences in liver metastasis prevalence attenuating across older age groups.
CONCLUSIONS AND RELEVANCE: Sex differences in liver metastases at diagnosis vary by primary site and age across gastrointestinal adenocarcinomas. Female sex is associated with lower prevalence of liver metastases in most tumor types, particularly in early-onset disease, except extrahepatic biliary cancers. These findings highlight sex as a clinically relevant variable associated with metastatic presentation.
PMID:43021572 | DOI:10.1093/oncolo/oyag437

